AUGMENTED OXYGEN DELIVERY THERAPEUTICS

描述：(改编自申请人的摘要)。通过 米切勒和伊利诺伊大学的合作伙伴关系， 调查人员试图将他们之前的发现归结为实践 能够产生新的氧运输疗法 增强的功能。一个完全合成的基因已经被构建出来了 这使得在细菌中生产克级的人血红蛋白 主持人。这种分离的材料结合了亚铁血红素，并组装成 一种功能性四聚体。通过对这一完全的基因改造 合成基因，研究人员产生了一种新的基因和 允许四聚体人血红蛋白融合的蛋白质结构 以多种多肽和蛋白质为基础的药理活性 化合物。 具体地说，他们建议产生一种蛋白质结合物，其中人类 血红蛋白四聚体通过二聚体与酶相连。 人类超氧化物歧化酶。生成的材质应显示 作为血液替代品的氧气输送的增强功能， 由于其聚集体尺寸的增加，以及一个新的新的 氧自由基清除功能。后一种能力， 以人血红蛋白作为载体以偶联物形式递送 血管寿命，在预防中应具有重要的临床效果 创伤或心肌梗死后的再灌注损伤。 建议的商业应用：不可用

DESCRIPTION: (Adapted from the applicant's abstract). Through the partnership of Myochlor and the University of Illinois, the investigators seek to reduce to practice their previous discovery which enables the generation of novel oxygen transporting therapeutics with augmented functionality. A totally synthetic gene has been constructed which allows the gram level production of human hemoglobin in bacterial hosts. This material, as isolated, incorporates heme and assembles into a functional tetramer. Through genetic modification of this totally synthetic gene , the investigators have produced a novel gene and protein structure which allows fusion of the tetrameric human hemoglobin to a variety of peptide and protein based pharmacologically active compounds. Specifically, they propose to generate a protein conjugate wherein human hemoglobin tetramers are linked through dimerization with the enzyme human superoxide dismutase. The resulting material should display augmented function with regard to oxygen delivery as a blood substitute, due to its increased aggregate size, as well as a novel new functionality of oxygen radical scavenging. The later capacity, delivered as a conjugate with human hemoglobin as a carrier with defined vascular lifetime, should have important clinical effects in preventing reperfusion injury following trauma or myocardial infarct. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE